Table 1.
Loss-of-Function Mutations in PLA2G7 and Cardiovascular Risk Factors among Study Participants.*
| Variable | Americans of European Ancestry | P Value† | Americans of African Ancestry | P Value† | ||
|---|---|---|---|---|---|---|
| Noncarriers (N = 8554) | Carriers (N = 10) | Noncarriers (N = 2301) | Carriers (N = 85) | |||
| Lipoprotein-associated phospholipase A2 (nmol/min/ml) | 238.5±60.7 | 84.6±49.4 | <0.001 | 199.5±54.5 | 113.2±32.8 | <0.001 |
| Age (yr) | 62.1±5.7 | 63.2±5.3 | 0.97 | 61.9±5.7 | 61.9±5.5 | 0.80 |
| Male sex (%) | 46.4 | 40.0 | 0.76 | 35.6 | 27.1 | 0.42 |
| Body-mass index‡ | 28.3±5.3 | 34.1±5.6 | 0.001 | 30.6±6.4 | 30.7±6.8 | 0.85 |
| Cholesterol (mg/dl) | ||||||
| Total | 201.1±36.3 | 198.0±34.1 | 0.79 | 199.4±38.4 | 205.8±36.0 | 0.13 |
| LDL | 122.3±32.6 | 118.5±37.4 | 0.71 | 123.4±36.1 | 129.4±33.4 | 0.13 |
| HDL | 49.0±16.3 | 47.3±11.9 | 0.74 | 53.2±16.9 | 52.7±16.7 | 0.80 |
| Triglycerides (mg/dl) | 151.7±88.4 | 161.0±54.2 | 0.74 | 115.7±65.6 | 118.2±62.3 | 0.73 |
| Hypertension (%) | 42.2 | 60.0 | 0.34 | 67.6 | 63.5 | 0.48 |
| Diabetes (%) | 13.8 | 10.0 | 1.00 | 27.2 | 32.1 | 0.32 |
| Currently smoking (%) | 14.0 | 20.0 | 0.64 | 17.7 | 14.8 | 0.66 |
| Use of statin medication (%) | 12.6 | 20.0 | 0.37 | 6.7 | 7.2 | 0.82 |
| Prevalent coronary heart disease (%) | 9.1 | 0.0 | 0.61 | 6.8 | 4.7 | 0.66 |
*
Plus–minus values are means ±SD. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. All measurements were obtained at clinic visit 4. HDL denotes high-density lipoprotein, and LDL low-density lipoprotein.
†
P values for mean differences between continuous variables were calculated with the use of the t-test, and P values for counts and percentages were calculated with the use of Fisher’s exact test.
‡
The body-mass index is the weight in kilograms divided by the square of the height in meters.